Lenalidomide is active in Japanese patients with symptomatic anemia in low- or intermediate-1 risk myelodysplastic syndromes with a deletion 5q abnormality

被引用文献12件参考文献19件

HARADA Hironori

Department of Hematology and Oncology, Hiroshima University
WATANABE Mitsumasa

Osaka Red Cross Hospital
SUZUKI Kenshi

Japan Red Cross Medical Center
YANAGITA Soshi

Shizuoka General Hospital
SUZUKI Takahiro

Division of Hematology, Jichi Medical University
YOSHIDA Yataro

Takeda General Hospital
KIMURA Akiro

Department of Hematology and Oncology, Hiroshima University
TSUDO Mitsuru

Osaka Red Cross Hospital
MATSUDA Akira

Department of Hematology, Saitama International Medical Center, Saitama Medical University
TOHYAMA Kaoru

Department of Laboratory Medicine, Kawasaki Medical School
TANIWAKI Masafumi

Department of Hematology and Oncology, Kyoto Prefectural University of Medicine
TAKESHITA Kenichi

Celgene K.K.
TAKATOKU Masaaki

Celgene K.K.
OZAWA Keiya

Division of Hematology, Jichi Medical University

この論文をさがす

International journal of hematology

International journal of hematology 90 (3), 353-360, 2009-10-15